Sjuksköterskans uppföljning av läkemedel i kommunens äldreomsorg : en empirisk studie med kvantitativ ansats

Bakgrund: Det är en vanlig arbetsuppgift för sjuksköterskan att följa upp effekt och eventuella biverkningar av läkemedelsbehandling för återkoppling till ordinerande läkare. I och med att sjuksköterskan i den kommunala äldrevården har en konsultativ roll, är informationen mellan henne och vårdpersonalen, som är nära patienten dygnet om, mycket viktig. Denna del av läkemedelskedjan är av central betydelse för att minska onödigt lidande för den äldre patienten i form av läkemedelsrelaterade problem. Syfte: Att kartlägga hur sjuksköterskan i kommunens äldreomsorg följer upp läkemedelsordinationer avseende effekt och biverkningar, särskilt i de fall när patienten själv inte har förmåga att uttrycka sitt mående i ord. Metod: En empirisk studie med kvantitativ ansats. En enkät utformades med frågor om vanligt förekommande arbetssituationer kring uppföljning av läkemedelsordination. Enkäten besvarades av trettiosju sjuksköterskor anställda i den kommunala äldrevården och i särskilda omsorgen, i två kommuner i Sverige. Resultat: Skriftlig rutin, hur uppföljning av läkemedelsordination ska utföras, saknades. Sjuksköterskan erhöll inte alltid direktiv från ordinerande läkare att/när/hur uppföljning skulle ske. Det var vanligt förekommande att en sjuksköterska lämnade ut läkemedel, och att en annan följde upp utfall av läkemedelsbehandlingen. Faktorer som kunde påverka resultatet av läkemedelsuppföljning var: hög arbetsbelastning på äldreboendet, frånvaro av ordinarie personal och vem av vårdpersonalen som rapporterade observationer under en uppföljningsperiod. Slutsats: För att stärka länkarna i läkemedelskedjan finns ett trängande behov av en övergripande instruktion hur sjuksköterskan ska följa upp läkemedelsbehandling

Mobile systems for monitoring Parkinson's disease

A challenge for the clinical management of Parkinson's disease (PD) is the large within- and between-patient variability in symptom profiles as well as the emergence of motor complications which represent a significant source of disability in patients. This thesis deals with the development and evaluation of methods and systems for supporting the management of PD by using repeated measures, consisting of subjective assessments of symptoms and objective assessments of motor function through fine motor tests (spirography and tapping), collected by means of a telemetry touch screen device. One aim of the thesis was to develop methods for objective quantification and analysis of the severity of motor impairments being represented in spiral drawings and tapping results. This was accomplished by first quantifying the digitized movement data with time series analysis and then using them in data-driven modelling for automating the process of assessment of symptom severity. The objective measures were then analysed with respect to subjective assessments of motor conditions. Another aim was to develop a method for providing comparable information content as clinical rating scales by combining subjective and objective measures into composite scores, using time series analysis and data-driven methods. The scores represent six symptom dimensions and an overall test score for reflecting the global health condition of the patient. In addition, the thesis presents the development of a web-based system for providing a visual representation of symptoms over time allowing clinicians to remotely monitor the symptom profiles of their patients. The quality of the methods was assessed by reporting different metrics of validity, reliability and sensitivity to treatment interventions and natural PD progression over time. Results from two studies demonstrated that the methods developed for the fine motor tests had good metrics indicating that they are appropriate to quantitatively and objectively assess the severity of motor impairments of PD patients. The fine motor tests captured different symptoms; spiral drawing impairment and tapping accuracy related to dyskinesias (involuntary movements) whereas tapping speed related to bradykinesia (slowness of movements). A longitudinal data analysis indicated that the six symptom dimensions and the overall test score contained important elements of information of the clinical scales and can be used to measure effects of PD treatment interventions and disease progression. A usability evaluation of the web-based system showed that the information presented in the system was comparable to qualitative clinical observations and the system was recognized as a tool that will assist in the management of patients.

Chloroquine is grossly under dosed in young children with malaria : implications for drug resistance

Background: Plasmodium falciparum malaria is treated with 25 mg/kg of chloroquine (CQ) irrespective of age. Theoretically, CQ should be dosed according to body surface area (BSA). The effect of dosing CQ according to BSA has not been determined but doubling the dose per kg doubled the efficacy of CQ in children aged <15 years infected with P. falciparum carrying CQ resistance causing genes typical for Africa. The study aim was to determine the effect of age on CQ concentrations. Methods and Findings: Day 7 whole blood CQ concentrations were determined in 150 and 302 children treated with 25 and 50 mg/kg, respectively, in previously conducted clinical trials. CQ concentrations normalised for the dose taken in mg/kg of CQ decreased with decreasing age (p<0.001). CQ concentrations normalised for dose taken in mg/m(2) were unaffected by age. The median CQ concentration in children aged <2 years taking 50 mg/kg and in children aged 10-14 years taking 25 mg/kg were 825 (95% confidence interval [CI] 662-988) and 758 (95% CI 640-876) nmol/l, respectively (p = 0.67). The median CQ concentration in children aged 10-14 taking 50 mg/kg and children aged 0-2 taking 25 mg/kg were 1521 and 549 nmol/l. Adverse events were not age/concentration dependent. Conclusions: CQ is under-dosed in children and should ideally be dosed according to BSA. Children aged <2 years need approximately double the dose per kg to attain CQ concentrations found in children aged 10-14 years. Clinical trials assessing the efficacy of CQ in Africa are typically performed in children aged <5 years. Thus the efficacy of CQ is typically assessed in children in whom CQ is under dosed. Approximately 3 fold higher drug concentrations can probably be safely given to the youngest children. As CQ resistance is concentration dependent an alternative dosing of CQ may overcome resistance in Africa.